Clinical experience with trimegestone as a new progestin in HRT.

Abstract

Trimegestone (TMG) is a novel, 19-norpregnane progestin, which demonstrates endometrial selectivity with a reduced progestin-related side effect profile when compared to several other currently marketed progestins. TMG has been studied in combination with 17beta-estradiol (17beta-E2) and conjugated equine estrogens (CEE). TMG-containing HRT agents were effective in relieving vasomotor symptoms and providing protection from endometrial hyperplasia with < or =1% hyperplasia. In clinical trials with sequential regimens, TMG provided predictable withdrawal bleeding associated with a low incidence of irregular and prolonged bleeding. Clinical studies of continuous combined regimens of estrogen/TMG combinations demonstrated high levels of amenorrhea. Both 17beta-E2 and CEE/TMG combinations have shown improved bone mineral density and quality-of-life assessments. Both continuous combined and sequential regimens of 17beta-E2/TMG and CEE/TMG have a favorable clinical profile. TMG provides an important new option for the treatment of postmenopausal symptoms and the prevention of osteoporosis.

• Authors: Gary Grubb, Daniele Spielmann, James Pickar, Ginger Constantine
• Journal: Steroids (Steroids) Vol. 68 Issue 10-13 Pg. 921-6 (Nov 2003) ISSN: 0039-128X [Print] United States
• PMID: 14667984 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Progestins
• trimegestone
• Estradiol
• Promegestone

Topics

• Adult
• Bone Density
• Clinical Trials as Topic
• Estradiol (metabolism)
• Female
• Hormone Replacement Therapy
• Humans
• Menopause (drug effects)
• Middle Aged
• Postmenopause
• Progestins (therapeutic use)
• Promegestone (analogs & derivatives, therapeutic use)
• Time Factors